EPA public review period for nootkatone to start in the US

July 1st, 2020

Photo: AdobeStock, Evolva License

July 1, 2020 – Evolva (SIX:EVE), the Swiss biotech company, announced today that a 15-day public review period for nootkatone started in the US. This is a further step in the registration process.

The public review period comes after the acceptance of all the studies submitted to the US Environmental Protection Agency (EPA), and allows the general public to share comments on nootkatone with the government agency.

Upon completion of the public notice period, the company expects the EPA to complete the registration of nootkatone quickly thereafter.

About the collaboration with CDC
Evolva has partnered with the Center of Disease Control and Prevention (CDC) since 2014. In 2017, Evolva was awarded a CDC Biomedical Advanced Research and Development Authority (BARDA) contract with the key objective of advancing the development of nootkatone and nootkatone-based products for protection against mosquito-borne diseases including dengue and Zika. This work has been funded with federal funds from CDC and managed by the Office of the Assistant Secretary for Preparedness and Response (ASPR), BARDA, under Contract No. HHSO100201700015C.

About Evolva

Evolva is a Swiss biotech company focused on the research, development and commercialization of ingredients based on nature. We have leading businesses in Flavors and Fragrances, Health Ingredients and Health Protection. Evolva’s employees, half of which are women, are dedicated to make the best products that can contribute to health, wellbeing and sensory enjoyment. Find out more at evolva.com.

For Evolva multimedia content, please visit: https://evolva.com/multimedia-library/.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

Barbara Duci
Head of Investor and Corporate Relations
+41 61 485 2003
+41 79 739 2636